Occam Recruits CEO of Prominent Rare Disease Research Foundation

Founded in 1983, the Charcot-Marie-Tooth Association is a non-profit dedicated to finding a cure for CMT and improving the quality of life for those affected by this rare neurological disorder.  Occam placed Suzanne “Sue” Bruhn, a biotech industry veteran, as the organization’s Chief Executive Officer in November 2023.

Sue brings over a decade of biotech CEO experience to CMTA and a strong commitment to rare disease drug development and patient advocacy dating back to her tenure at Shire.  Suzanne has a Ph.D. in Chemistry from MIT and completed her post-doctoral work at Harvard Medical School.  She currently sits on the boards of Pliant Therapeutics, Travere Therapeutics, Vigil Neuroscience, and MindMed.

Occam’s work with CMTA is part of the firm's executive search practice for life science-focused foundations and non-profit organizations.  Having successfully partnered with esteemed non-profits such as Gavi, the Vaccine Alliance, and theBill & Melinda Gates Foundation in the past, we are gratified by the opportunity to continue to apply our efforts toward philanthropic endeavors.